Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI doctor in the ICU: can ChatGPT-5 save lives?

NCT ID NCT07293078

Knowledge-focused Sponsor: MetroWest Artificial Intelligence Research Workgroup Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an AI model (ChatGPT-5) can help doctors make better decisions for critically ill patients in the intensive care unit (ICU). About 1000 adults admitted to the ICU will be randomly assigned to standard care or care where the AI provides diagnostic and treatment suggestions. The goal is to see if the AI reduces medical errors and improves outcomes like survival and hospital stay length.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ChatGPT-5 (a large language model used for decision support)
What this could lead to
If successful, this could show that AI helps reduce medical errors in the ICU, potentially leading to safer care for critically ill patients.
What could go wrong
This is an early-phase trial (Phase 1/2) with 1000 patients, so results may not apply broadly. The AI's recommendations might not always be accurate or helpful, and there is a risk of over-reliance on technology.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (≥ 18 years) admitted to the medical intensive care unit (MICU) at participating hospitals. 2. Direct admissions from the emergency department or transfers from medical wards to the MICU. 3. Critically ill patients meeting local ICU admission criteria. Exclusion Criteria: 1. Transfers to the MICU from outside hospitals, operating room, or post-anesthesia care unit. 2. Age \< 18 years. 3. Incomplete or missing essential clinical information at admission (e.g., key labs or documentation not yet available). 4. Primary surgical or cardiac (e.g., STEMI) patients. 5. Pregnant or postpartum women. 6. Prisoners.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury acute respiratory failure Confusion Critical Illness delirium infectious disease with sepsis multiple organ dysfunction syndrome Sepsis Shock

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury Acute respiratory failure (ARF) Critical illness Delirium confusional state Multi organ failure Sepsis Shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Framingham Union Hospital/MetroWest Medical Center

    Framingham, Massachusetts, 01702, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.